

July 10, 1970

Mr. Joseph Lelyveld
The New York Times
229 West 43rd Street
New York, New York

Dear Mr. Lelyveld:

I was pleased to have the opportunity today to continue our conversation, although, I must admit, that I was distressed by the turn of events.

The summary of the June 4 meeting on *Narcotic Antagonists in Opiate Dependence* is enclosed, with a list of participants. This summary has been accepted for publication in *Science*.

We have been notified by representatives of the Endo Division of DuPont - Mr. Joseph Conlon, Vice-President of DuPont and two associates - that they would no longer support studies of naloxone in the therapy of opiate dependence; specifically, they would not approve studies under their IND (Investigational New Drug Application) before the FDA, nor would they make supplies available for clinical trials.

I indicated that we were prepared to purchase a supply sufficient for our immediate needs, 6 kilograms, at an approximate price of \$10,000 per kilogram - a price suggested in 1969 by Mr. David Kline of Endo Laboratories. Mr. Conlon asked us not to make this request since it was unlikely that they would honor it.

Our request was sent today, and a copy is enclosed. Also, a copy of a letter sent to other participants of the June 4 meeting.

Our aim is to obtain supplies of naloxone for clinical trial. We have no need to embarrass either Endo or DuPont in their unfortunate decision. Any help you can give us to attain our primary goal will be appreciated. Failing that, we will cooperate fully to make the complete antagonist story available to the American press - a story with many strange and sordid elements.

Mr. Lelyveld

-2-

July 10, 1970

Incidentally, we have also brought this issue to the attention of Mr. Earl Ubell of CBS News, a friend and follower of our work, and for whom we have served as *ad hoc* consultants on numerous occasions.

Thank you in advance for your help.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kt